Krugliak Cleveland, Noa
St-Pierre, Joƫlle
Kellar, Amelia
Rubin, David T.
Article History
Accepted: 3 January 2024
First Online: 20 January 2024
Declarations
:
: The authors declare no conflict interests.
: The authors declare no competing interests.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: JS-P and AK report no relevant disclosures. NKC serves as a consultant to Takeda and for NeuroLogica, a subsidiary of Samsung Electronics, and as a speaker for Bristol-Myers Squibb. DTR has received grant support from Takeda; and has served as a consultant for Abbvie, Alimentiv Inc., Altrubio, Amgen, Avalo Therapeutics, Bristol-Myers Squibb, Buhlmann Diagnostics Corp, ClostraBio, Connect BioPharma, Datos Health Ltd, EcoR1, Evinature Ltd, Ferring Pharma, Image Analysis Group (IAG), Iterative Health, Janssen Pharmaceuticals, Lilly Eli & Co, Menten AI, Odyssey Thera, Pfizer, Prometheus Biosciences, Reistone Biopharma, Samsung Neurologica, Sangamo Therapeutics, Shanghai Pharma Biotherapeutics USA, Takeda, Target RWE, Tissium S.A., and Trellus Health.